Mind the gap in kidney care: translating what we know into what we do.

Competing Interests: VA Luyckx is chair of the Advocacy Working Group of the International Society of Nephrology and has no financial disclosures. KR Tuttle has received research grants from the National Institutes of Health (National Institute of Diabetes and Digestive and Kidney Diseases, National Heart, Lung, and Blood Institute, National Center for Advancing Translational Sciences, National Institute on Minority Health and Health Disparities, director’s office), the United States Centers for Disease Control and Prevention, and Travere Therapeutics; and consultancy fees from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. She is also chair of the Diabetic Kidney Disease Collaborative for the American Society of Nephrology. R Correa-Rotter is a member of the Steering Committee for World Kidney Day, a member of the Diabetes Committee of the Latin American Society of Nephrology and Hypertension, and a member of the Latin American Regional Board of the International Society of Nephrology. He is also a member of the Steering Committees for the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial (AstraZeneca), the Study Of diabetic Nephropathy with AtRasentan (SONAR) [AbbVie], A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting (FINE-REAL) [Bayer], and CKD-ASI (Boehringer Ingelheim). He has received research grants from AstraZeneca, GlaxoSmithKline, Roche, Boehringer Ingelheim, and Novo Nordisk, as well as speaker honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, and Amgen. All other authors have declared no competing interests.